These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 24725383)

  • 1. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis.
    Sumiyoshi S; Yoshizawa A; Sonobe M; Kobayashi M; Sato M; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Jun; 84(3):281-8. PubMed ID: 24725383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MUC5AC and MUC5B enhance the characterization of mucinous adenocarcinomas of the lung and predict poor prognosis.
    Kim YK; Shin DH; Kim KB; Shin N; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Kim MH
    Histopathology; 2015 Oct; 67(4):520-8. PubMed ID: 25786562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
    Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MUC5AC enhances tumor heterogeneity in lung adenocarcinoma with mucin production and is associated with poor prognosis.
    Dong Y; Zhou L; Zhao D; Li K; Liu Z; Che N; Liu H
    Jpn J Clin Oncol; 2020 Jun; 50(6):701-711. PubMed ID: 32083303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reciprocal expression of trefoil factor-1 and thyroid transcription factor-1 in lung adenocarcinomas.
    Matsubara D; Yoshimoto T; Soda M; Amano Y; Kihara A; Funaki T; Ito T; Sakuma Y; Shibano T; Endo S; Hagiwara K; Ishikawa S; Fukayama M; Murakami Y; Mano H; Niki T
    Cancer Sci; 2020 Jun; 111(6):2183-2195. PubMed ID: 32237253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.
    Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Fujimoto M; Kawakami F; Tsuruyama T; Travis WD; Date H; Haga H
    J Thorac Oncol; 2013 Jan; 8(1):52-61. PubMed ID: 23242438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lung non-terminal respiratory unit type adenocarcinoma: a clinicopathologic study].
    Liu B; Wu N; Shen Q; Shi SS; Zhang SS; Ru Y; Rao Q; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):603-608. PubMed ID: 30107665
    [No Abstract]   [Full Text] [Related]  

  • 8. Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers.
    Duruisseaux M; Antoine M; Rabbe N; Rodenas A; Mc Leer-Florin A; Lacave R; Poulot V; Duchêne B; Van Seuningen I; Cadranel J; Wislez M
    Lung Cancer; 2017 Jul; 109():92-100. PubMed ID: 28577958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas.
    Seo AN; Yang JM; Kim H; Jheon S; Kim K; Lee CT; Jin Y; Yun S; Chung JH; Paik JH
    Br J Cancer; 2014 May; 110(11):2688-99. PubMed ID: 24809777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.
    Chung KP; Huang YT; Chang YL; Yu CJ; Yang CH; Chang YC; Shih JY; Yang PC
    Chest; 2012 Feb; 141(2):420-428. PubMed ID: 21799026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
    Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
    J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
    Johnson ML; Sima CS; Chaft J; Paik PK; Pao W; Kris MG; Ladanyi M; Riely GJ
    Cancer; 2013 Jan; 119(2):356-62. PubMed ID: 22810899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivating mutations and hypermethylation of the NKX2-1/TTF-1 gene in non-terminal respiratory unit-type lung adenocarcinomas.
    Matsubara D; Soda M; Yoshimoto T; Amano Y; Sakuma Y; Yamato A; Ueno T; Kojima S; Shibano T; Hosono Y; Kawazu M; Yamashita Y; Endo S; Hagiwara K; Fukayama M; Takahashi T; Mano H; Niki T
    Cancer Sci; 2017 Sep; 108(9):1888-1896. PubMed ID: 28677170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS mutation-positive bronchial surface epithelium (BSE)-type lung adenocarcinoma with strong expression of TTF-1: a case providing a further insight as for the role of TTF-1 in the oncogenesis.
    Takanashi Y; Tajima S; Hayakawa T; Neyatani H; Funai K
    Int J Clin Exp Pathol; 2015; 8(11):15338-43. PubMed ID: 26823891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A favourable prognostic marker for EGFR mutant non-small cell lung cancer: immunohistochemical analysis of MUC5B.
    Wakata K; Tsuchiya T; Tomoshige K; Takagi K; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Whitsett JA; Maeda Y; Nagayasu T
    BMJ Open; 2015 Jul; 5(7):e008366. PubMed ID: 26224019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas.
    Sonobe M; Kobayashi M; Ishikawa M; Kikuchi R; Nakayama E; Takahashi T; Menju T; Takenaka K; Miyahara R; Huang CL; Okubo K; Bando T; Date H
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S347-54. PubMed ID: 21607772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
    Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
    Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.